Back to full list of clinical trials

Ongoing clinical trials for non-alcoholic steatohepatitis: Actively recruiting


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at preventing the progression of liver fibrosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH; willing to commit to a 2 year study with visits twice a month. Clinical Trials.gov identifier: NCT01672866

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at reversing liver scarring and heal cirrhosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH and cirrhosis; willing to commit to a 2 year study with visits twice a month; Clinical Trials.gov identifier: NCT01672879

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670

Back to Top